Wednesday, November 22, 2023 The upcoming CCTG NE2 (STOPNET) trial was presented at the 25th Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting that was held in Aotearoa New Zealand from November 13 – 16. CCTG NE2 trial is a randomized study of cessation of somatostatin analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine tumours. This trial will investigate whether it is worthwhile for neuroendocrine tumor (NET) patients to continue somatostatin analogue (SSA) therapy after treatment with peptide radionuclide therapy (PRRT). The study proposes to stop SSA injections for some patients following PRRT for researchers to compare tumour growth, side effects and quality of life with patients who continue SSA injections. AGITG will lead the international study and CCTG will conduct the trial in Canada with co-chairs Dr Rachel Goodwin, Ottawa Hospital and Dr Jonathan Loree, BC Cancer. It will generate data to inform the feasibility and design of a subsequent larger clinical trial and will inform public health decisions and treatment guidelines. About AGITG The group is a multi-disciplinary collaborative group of medical research professionals who conduct clinical trials and related biological research to improve treatments for gastrointestinal cancers.
